drugset / Trial / NCT02817347
A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
RandomizedParallel-groupDouble-blindTreatment
Summary
In patients with otitis media presenting with otoscopy-confirmed otorrhea who had tympanostomy tube insertion or tympanic perforation, to evaluate the safety, tolerability, and the proportion of patients with cessation of otorrhea after ear-drop administration of YH1177 or YH1177-D for 14 days and therefore to determine the optimal clinical dose.
Timeline
- Start
- 2016-06
- Primary completion
- 2017-04-13
- Completion
- 2017-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.1 % | Topical |
| Subject | Piperacillin | Small molecule | 2 % | Topical |
| Subject | Piperacillin | Small molecule | 4 % | Topical |
| Subject | Piperacillin | Small molecule | 8 % | Topical |
| Subject | Tazobactam | Small molecule | 0.25 % | Topical |
| Subject | Tazobactam | Small molecule | 0.5 % | Topical |
| Subject | Tazobactam | Small molecule | 1 % | Topical |